Literature DB >> 12434520

Metallothionein provides ubiquinone-mediated neuroprotection in Parkinson's disease.

Manuchair Ebadi1, Sushil Sharma, Dhanasekaran Muralikrishnan, Shaik Shavali, Josh Eken, Patcharee Sangchot, Banthit Chetsawang, Leah Brekke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12434520

Source DB:  PubMed          Journal:  Proc West Pharmacol Soc        ISSN： 0083-8969


× No keyword cloud information.
  4 in total

Review 1.  Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease.

Authors:  Manuchair Ebadi; Holly Brown-Borg; Hesham El Refaey; Brij B Singh; Scott Garrett; Shaik Shavali; Sushil K Sharma
Journal:  Brain Res Mol Brain Res       Date:  2005-03-24

2.  Covalent arylation of metallothionein by oxidized dopamine products: a possible mechanism for zinc-mediated enhancement of dopaminergic neuron survival.

Authors:  Michelle A Gauthier; Joseph K Eibl; James A G Crispo; Gregory M Ross
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

Review 3.  Clinical significance of metallothioneins in cell therapy and nanomedicine.

Authors:  Sushil Sharma; Afsha Rais; Ranbir Sandhu; Wynand Nel; Manuchair Ebadi
Journal:  Int J Nanomedicine       Date:  2013-04-16

4.  Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.

Authors:  Tatsuya Yamamoto; Tomoyuki Uchiyama; Yoshinori Higuchi; Masato Asahina; Shigeki Hirano; Yoshitaka Yamanaka; Satoshi Kuwabara
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.